Skip to main content
Top
Published in: Acta Diabetologica 1/2010

01-03-2010 | Original Article

Profile of patients with diabetes in Eritrea: results of first phase registry analyses

Authors: Berhane Seyum, Goitom Mebrahtu, Abdulmumini Usman, Jacob Mufunda, Beyene Tewolde, Solomon Haile, Andrew Kosia, Ermias Negassi

Published in: Acta Diabetologica | Issue 1/2010

Login to get access

Abstract

A cross-sectional descriptive study was done on patients recently entered into the National Diabetes Registry in Eritrea where the prevalence was estimated to be 2.2% based on patient information in 2004. Of the 627 patients with diabetes, two thirds were type 2. Although type 1 had poorer control (42.9%) than type 2 (29.9%), some of the risk factors such as cholesterol (43.4 vs. 28.2%), triglyceride (23.4 vs. 12.8%), hypertension (55.2 vs. 12.7%) as well as BMI and waist/hip ratio were higher in type 2 than type 1. More than one-third (41.2%) of patients with type 2 compared to type 1 (19.5%) had complications, the commonest being retinopathy (33%) followed by foot ulcers (14%) and neuropathy (4%). Many of the diabetic patients demonstrated the presence of the metabolic syndrome components such as hypertension, obesity and dyslipidemia. The authors conclude that diabetes registry is invaluable in providing evidence-based prevention and control of the disease.
Literature
1.
go back to reference Adeghate E, Schattner P, Dunn E (2006) An update on the etiology and epidemiology of diabetes mellitus. Ann New York Acad Sci 1084:1–29CrossRef Adeghate E, Schattner P, Dunn E (2006) An update on the etiology and epidemiology of diabetes mellitus. Ann New York Acad Sci 1084:1–29CrossRef
2.
go back to reference Mbanya JC, Sobngwi E (2003) Diabetes in Africa diabetes micro vascular and macro vascular disease in Africa. J Cardiovasc Risk 10:97–102CrossRefPubMed Mbanya JC, Sobngwi E (2003) Diabetes in Africa diabetes micro vascular and macro vascular disease in Africa. J Cardiovasc Risk 10:97–102CrossRefPubMed
3.
go back to reference Mufunda J, Nyarango P, Kosia A, Ogbamariam A, Mebrahtu G, Usman A et al (2005) Non-communicable diseases in Africa: a silent hypertension epidemic in Eritrea. J Hum Hypertens 19:255–256PubMed Mufunda J, Nyarango P, Kosia A, Ogbamariam A, Mebrahtu G, Usman A et al (2005) Non-communicable diseases in Africa: a silent hypertension epidemic in Eritrea. J Hum Hypertens 19:255–256PubMed
4.
go back to reference Mufunda J, Chatora R, Ndambakuwa Y, Nyarango P, Kosia A, Chifamba J et al (2006) Emerging non-communicable disease epidemic in Africa: preventive measures from the WHO Regional Office for Africa. Ethn Dis 16:521–526PubMed Mufunda J, Chatora R, Ndambakuwa Y, Nyarango P, Kosia A, Chifamba J et al (2006) Emerging non-communicable disease epidemic in Africa: preventive measures from the WHO Regional Office for Africa. Ethn Dis 16:521–526PubMed
5.
go back to reference Usman A, Mebrahtu G, Mufunda J, Nyarango P, Hagos G, Kosia A et al (2006) Prevalence of non communicable disease risk factors in Eritrea. Ethn Dis 16:542–546PubMed Usman A, Mebrahtu G, Mufunda J, Nyarango P, Hagos G, Kosia A et al (2006) Prevalence of non communicable disease risk factors in Eritrea. Ethn Dis 16:542–546PubMed
6.
go back to reference Mufunda J, Mebrahtu G, Usman A, Nyarango P, Kosia A, Ghebrat Y, Ogbamariam A, Masjuan M, Gebremichael A (2006) Prevalence of hypertension in Eritrea and its relationship with obesity: results from a national blood pressure survey. J Hum Hypertens 20(1):59–65CrossRefPubMed Mufunda J, Mebrahtu G, Usman A, Nyarango P, Kosia A, Ghebrat Y, Ogbamariam A, Masjuan M, Gebremichael A (2006) Prevalence of hypertension in Eritrea and its relationship with obesity: results from a national blood pressure survey. J Hum Hypertens 20(1):59–65CrossRefPubMed
7.
go back to reference Sharp P, Rainbow S (2002) Continuous glucose monitoring and hemoglobin A1C. Ann Clin Biochem 39:516–517CrossRefPubMed Sharp P, Rainbow S (2002) Continuous glucose monitoring and hemoglobin A1C. Ann Clin Biochem 39:516–517CrossRefPubMed
8.
go back to reference Manley S (2003) Haemoglobin A1c—a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med 41:1182–1190CrossRefPubMed Manley S (2003) Haemoglobin A1c—a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med 41:1182–1190CrossRefPubMed
9.
go back to reference Carinci F, Federici MO, Benedetti MM (2006) Diabetes registers and prevention strategies: towards an active use of health information. Diabetes Res Clin Pract 74(Suppl 2):S215–S219CrossRef Carinci F, Federici MO, Benedetti MM (2006) Diabetes registers and prevention strategies: towards an active use of health information. Diabetes Res Clin Pract 74(Suppl 2):S215–S219CrossRef
10.
go back to reference Georgioou A, Burns J, McKenzie S, Penn D, Flack J, Harris MF (2006) Monitoring change in diabetes care using diabetes registers-experience from divisions of general practice. Aust Fam Phys 35:77–80 Georgioou A, Burns J, McKenzie S, Penn D, Flack J, Harris MF (2006) Monitoring change in diabetes care using diabetes registers-experience from divisions of general practice. Aust Fam Phys 35:77–80
11.
go back to reference Abdul-Ghani M, Nawaf G, Nawaf F, Itzhak B, Minuchin O, Vardi P (2006) Increased prevalence of micro vascular complications in type 2 diabetes patients with the metabolic syndrome. Isr Med Assoc J 8:424–425 Abdul-Ghani M, Nawaf G, Nawaf F, Itzhak B, Minuchin O, Vardi P (2006) Increased prevalence of micro vascular complications in type 2 diabetes patients with the metabolic syndrome. Isr Med Assoc J 8:424–425
12.
go back to reference Swai AB, Kitange HM, Masuki G, Kilima PM, Alberti KG, McLarty DG (1992) Is diabetes mellitus related to undernutrition in rural Tanzania? BMJ 305:1057–1062CrossRefPubMed Swai AB, Kitange HM, Masuki G, Kilima PM, Alberti KG, McLarty DG (1992) Is diabetes mellitus related to undernutrition in rural Tanzania? BMJ 305:1057–1062CrossRefPubMed
13.
go back to reference Cuissnier-Raynall JC, Ducorps M, Grandpierre G (1985) Tropical diabetes mellitus, a new nutritional indicator. Med Trop 45:179–184 Cuissnier-Raynall JC, Ducorps M, Grandpierre G (1985) Tropical diabetes mellitus, a new nutritional indicator. Med Trop 45:179–184
14.
go back to reference Sleight P, Pouleur H, Zannad F (2006) Benefits, challenges, and registrability of the polypill. Eur Heart J 27:1651–1656CrossRefPubMed Sleight P, Pouleur H, Zannad F (2006) Benefits, challenges, and registrability of the polypill. Eur Heart J 27:1651–1656CrossRefPubMed
15.
go back to reference Gaziano TA, Opie LH, Weinsterin MC (2006) Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 368:679–686CrossRefPubMed Gaziano TA, Opie LH, Weinsterin MC (2006) Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 368:679–686CrossRefPubMed
16.
go back to reference Siraj ES, Sevoum B, Saenz C, Abdulkadir J (2006) Lipid and lipoprotein profiles in Ethiopians with diabetes mellitus. Metabolism 55:706–710CrossRefPubMed Siraj ES, Sevoum B, Saenz C, Abdulkadir J (2006) Lipid and lipoprotein profiles in Ethiopians with diabetes mellitus. Metabolism 55:706–710CrossRefPubMed
17.
go back to reference Kulenovic I, Rasic S, Karcic S (2006) Development of micro vascular complications in type 1 diabetic patients 10 years follow up. Bosn J Basic Med Sci 6:47–50PubMed Kulenovic I, Rasic S, Karcic S (2006) Development of micro vascular complications in type 1 diabetic patients 10 years follow up. Bosn J Basic Med Sci 6:47–50PubMed
18.
go back to reference Sokolnicki LA, Roberts SK, Wilkins BW, Basu A, Charkoudian N (2007) Contribution of nitric oxide to cutaneous micro vascular dilation in individuals with type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 292:E314–E318CrossRefPubMed Sokolnicki LA, Roberts SK, Wilkins BW, Basu A, Charkoudian N (2007) Contribution of nitric oxide to cutaneous micro vascular dilation in individuals with type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 292:E314–E318CrossRefPubMed
19.
go back to reference Kasaloya Z, Prazny M, Skrha J (2006) Relationship between peripheral diabetic neuropathy and micro vascular reactivity in patients with type 1 and type 2 diabetes mellitus—neuropathy and microcirculation. Exp Clin Endocrinol Diabet 114:52–57CrossRef Kasaloya Z, Prazny M, Skrha J (2006) Relationship between peripheral diabetic neuropathy and micro vascular reactivity in patients with type 1 and type 2 diabetes mellitus—neuropathy and microcirculation. Exp Clin Endocrinol Diabet 114:52–57CrossRef
20.
go back to reference Ogbera AO, Fasanmade O, Ohwovoriole AE, Adediran O (2006) An assessment of the disease burden of foot ulcers in patients with diabetes mellitus attending a teaching hospital in Lagos, Nigeria. Int J Low Extrem Wounds 5:244–249CrossRefPubMed Ogbera AO, Fasanmade O, Ohwovoriole AE, Adediran O (2006) An assessment of the disease burden of foot ulcers in patients with diabetes mellitus attending a teaching hospital in Lagos, Nigeria. Int J Low Extrem Wounds 5:244–249CrossRefPubMed
Metadata
Title
Profile of patients with diabetes in Eritrea: results of first phase registry analyses
Authors
Berhane Seyum
Goitom Mebrahtu
Abdulmumini Usman
Jacob Mufunda
Beyene Tewolde
Solomon Haile
Andrew Kosia
Ermias Negassi
Publication date
01-03-2010
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 1/2010
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-009-0093-8

Other articles of this Issue 1/2010

Acta Diabetologica 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine